Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 January 1999

Effect of probucol on plasma apolipoproteins C-III in Apo B- and non-Apo B - containing lipoproteins in patients with cardiovascular artery disease

Barbara Millo, Barbara Torbus-Lisiecka, Zdzisława Kornacewicz-Jach, Marek Naruszewicz

Med Sci Monit 1999; 5(1): CR111-117 :: ID: 505270

Abstract

The distribution of apolipoproteins C-III (apo C-III) among lipoproteins may be causatively associated with cardiovascular artery disease (CAD). The objective of this study was to evaluate the changes in plasma concentration of lipids, lipoproteins and apolipoproteins in CAD patients, qualified for coronary by-pass surgery, before and after short-time administration of probucol. 19 patients (mean 53±12 years) with angiographically confirmed cardiovascular artery disease were treated with probucol (2x500 mg/day) for 3 weeks. Patients were evaluated before and after the drug administration. Levels of total apolipoproteins C-III (apo C-III) and apo C-III in plasma devoided of apo B-containig particles (apo C-III-nonLp-B) by immunoprecipitation using specific anti-apo B antiserum, were measured by electroimmunoassay. Apo C-III concentrations in apo B-containing lipoproteins (apo-C-III-LpB) were calculated by difference between total and apo C-III-nonLpB. Almost all lipid parameters significantly decreased after probucol therapy: total cholesterol from 254.8±40.1 to 213.3±44.5 mg/dl, LDL-cholesterol from 181.5±37.0 to 141±38.9 mg/dl, HDL from 40.0±5.3 to 33.6±5.5 mg/dl, triglycerides from 153.3±35.5 to 128.0±48.1mg/dl. Total apoC-III decreased from 27.3±7.2 to 23.2±8.5 mg/l, apo C-III-nonLpB from 18.8±6.8 to 13.2±5.1 mg/l, the apo C-III ratio (apo C-III-nonLp- B/apo C-III-Lp-B) changed from 2.55±1.56 to 1.47±0.63. The relationship between apo C-III, apo C-III-non- Lp-B, apo C-III-Lp-B and triglycerides remarkably changed after probucol therapy: r=0.41 (NS) vs. r=0.80 (p<0.001); r=0.42 (NS) vs. r=0.78 (p<0.001) and r=0.04 (NS) vs. r=0.55 (p<0.05), respectively. The different relationship was observed also between apo C-III-Lp-B and HDL3-cholesterol (r = -0.45, p<0.05 vs. r =-0.07, NS) Our results confirmed that probucol influences on lipid metabolism and apo C-III is involved in this process. Probucol decreased apo C-III mainly in lipoproteins without apo B, it was possible that probucol rearranged the action of apo-C-IIILpB.

Keywords: CAD, Probucol, Apolipoprotein C-III

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750